 Enlivex Therapeutics Ltd. Enlivex or the Company ENLV today announced that it has withdrawn its previously announced proposed underwritten public offering of ordinary shares due to market conditions. The Company currently believes that it is not in the best interest of its shareholders to raise equity capital in the current market environment. The Company remains well capitalized with cash and cash equivalents, together with short term deposits, of approximately 13.5 million as of September 30, 2019, which the Company believes will be sufficient to fund its current operations through the beginning of the second quarter of 2021. 